José Luis
Pérez Gracia
Consultor Médico
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublicaciones en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (5)
2021
2020
-
Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study
Journal of Clinical Oncology, Vol. 38, Núm. 14, pp. 1580-1591
2019
-
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial
Annals of Oncology, Vol. 30, Núm. 2, pp. 281-289
2017
-
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
The Lancet, Vol. 389, Núm. 10064, pp. 67-76
2016
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial
The Lancet, Vol. 387, Núm. 10027, pp. 1540-1550